Gallery
Picture 1
Mnkd stock price movements have been closely tied to
New with box
Oops! Looks like we're having trouble connecting to our server.
Refresh your browser window to try again.
mnkd stock price movements have been closely tied to FDA updates in recent sessions. Investors are watching whether regulatory clarity on inhaled insulin expands market adoption, which could shift valuation multiples upward. MannKind Corporation (NASDAQ:MNKD) develops inhaled therapies for diabetes, with Afrezza as its key product. This rapid-acting inhaled insulin mimics the body’s natural insulin response, working within 12-15 minutes and clearing in 2-3 hours for better blood sugar control. Its small, needle-free inhaler is easy to use, and pre-measured doses ensure accuracy. The company also earns revenue from Afrezza and other diabetes products like the V-Go insulin delivery device. Wall Street analysts have issued reports on $MNKD in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings. As of this week, mnkd stock price reflects cautious optimism from institutional buyers, hovering near $4.